Respiratory syncytial virus (RSV) is a common viral infection that may lead to serious complications in certain groups. Since 2023, vaccines are now available and are highly recommended, especially ...
A common respiratory virus, respiratory syncytial virus, is surging in the United States, leading to some children's hospitals being overwhelmed. The influenza virus is also on the rise, along with ...
A new scoping review examines the impact of respiratory bacteria on the severity of respiratory syncytial virus (RSV) infections and long-term health outcomes in children. By synthesizing data from 33 ...
In early April, Pfizer announced a $525 million acquisition of ReViral’s novel therapy for respiratory syncytial virus (RSV). Since then, RSV therapies have garnered renewed global attention. However, ...
WASHINGTON, DC - JULY 21: COVID-19 Response Coordinator Ashish Jha speaks to reporters during a ... More press briefing at the White House July 21, 2022 in Washington, DC. (Photo by Drew Angerer/Getty ...
In a recent study posted to the medRxiv* preprint server, researchers from Germany conducted a population-based surveillance study to ascertain the etiology of community-acquired pneumonia (CAP) ...
Respiratory syncytial virus (RSV) mimics the symptoms of a really bad cold. It is especially dangerous for premature babies and children with existing lung or heart ailments and generally requires ...
What is mResvia used for? mResvia (respiratory syncytial virus vaccine) is commonly given to help prevent lower respiratory tract disease (such as pneumonia or bronchiolitis) caused by respiratory ...
In a recent study posted to the medRxiv* preprint server, a team of researchers explored the association between Streptococcus pneumoniae and severe acute respiratory syndrome coronavirus 2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback